GlassScriptPhysician profile
Vishal Aggarwal
NPI 1295705663
$3,907.98
in general payments reported to CMS, 2019-2025
32 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $544 · 2021: $757 · 2022: $575 · 2023: $626 · 2024: $489 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $556.54 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $530.72 | 2019-2025 | Ofev, Jardiance |
| Janssen Pharmaceuticals, INC | $504.56 | 2019-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $254.92 | 2019-2023 | Arexvy, Shingrix |
| Abbvie INC. | $237.73 | 2021-2025 | Vraylar |
| Corium, LLC | $236.74 | 2022-2023 | Azstarys, Adlarity |
| Novo Nordisk INC | $192.97 | 2019-2025 | |
| Biogen, INC. | $149.79 | 2021-2023 | Skyclarys |
| Pfizer INC. | $142.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $123.37 | 2020-2022 | |
| Abbott Laboratories | $112.38 | 2020-2024 | Freestyle Libre 3 |
| Allergan, INC. | $101.56 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.19 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $74.50 | 2024-2025 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $56.61 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $55.86 | 2024 | Gemtesa |
| Almatica Pharma LLC | $55.25 | 2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $55.21 | 2024-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $54.30 | 2019-2020 | |
| Amgen INC. | $50.72 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.24 | 2024 | |
| Organogenesis INC. | $33.39 | 2025 | Cygnus Dual |
| Lundbeck LLC | $33.14 | 2023 | Rexulti |
| Eisai INC. | $31.79 | 2025 | |
| Mylan Specialty L.P. | $24.75 | 2023 | Yupelri |
| Medtronic, INC. | $21.99 | 2025 | Inceptiv |
| Scilex Pharmaceuticals INC. | $21.84 | 2023 | Ztlido |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.16 | 2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $15.79 | 2021 | |
| Currax Pharmaceuticals LLC | $15.43 | 2025 | Contrave |
| Kowa Pharmaceuticals America, INC. | $14.92 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.84 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Aggarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.